Sacubitril-valsartan: novel therapy for heart failure
- PMID: 28904036
- PMCID: PMC5597015
Sacubitril-valsartan: novel therapy for heart failure
References
-
- McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. - PubMed
-
- Latour-Pérez J, Coves-Orts FJ, Abad-Terrado C, Abraira V, Zamora J. Accuracy of B-type natriuretic peptide levels in the diagnosis of left ventricular dysfunction and heart failure: a systematic review. Eur J Heart Fail. 2006;8(4):390–9. - PubMed
-
- Lindblad AJ, Allan GM. Aldosterone antagonists in systolic heart failure. Can Fam Physician. 2014;60:e104. Available from: www.cfp.ca/content/cfp/60/2/e104.full.pdf. Accessed 2017 Jul 28. - PMC - PubMed
-
- Moe GW, Ezekowitz JA, O’Meara E, Lepage S, Howlett JG, Fremes S, et al. The 2014 Canadian Cardiovascular Society heart failure management guidelines focus update: anemia, biomarkers, and recent therapeutic trial implications. Can J Cardiol. 2015;31(1):3–16. Erratum in: Can J Cardiol 2016;32(3):394. - PubMed
-
- Howlett JG, Chan M, Ezekowitz JA, Harkness K, Heckman GA, Kouz S, et al. The Canadian Cardiovascular Society heart failure companion: bridging guidelines to your practice. Can J Cardiol. 2016;32(3):296–310. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical